<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45443">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514681</url>
  </required_header>
  <id_info>
    <org_study_id>JBCRG-M05</org_study_id>
    <nct_id>NCT02514681</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Locally Advanced and Metastatic Breast Cancer(Study of Perjeta Re-treatment for Clinical Outcomes)</brief_title>
  <acronym>PRECIOUS</acronym>
  <official_title>A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Locally Advanced and Metastatic Breast Cancer(Study of Perjeta Re-treatment for Clinical Outcomes)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of pertuzumab, trastuzumab
      and chemotherapy as a pertuzumab retreatment compared to trastuzumab and chemotherapy in
      locally advanced or metastatic breast cancer patients for previously treated with pertuzumab
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (assessed by investigators)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (assessed by independent review)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS in patients treated with trastuzumab emtansine (T-DM1) as the latest regimen</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response, Overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported-outcome</measure>
    <time_frame>4 years</time_frame>
    <description>Difference in terms of patient-reported outcome (PRO) between standard group and Pertuzumab treated group FACT-G, FACT-B and EQ-5D are used as assessment tools for PRO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Incidence/Grade of Serious Adverse Events (SAEs), Pertuzumab-specific adverse events, laboratory abnormalities Percentage and number of subjects who discontinued for adverse event.</measure>
    <time_frame>4 years</time_frame>
    <description>Safety for HER2-positive locally advanced or metastatic breast cancer subjects who were previously treated with Pertuzumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>4 years</time_frame>
    <description>To find Prognostic and predictive biomarker markers for patients receiving anti-HER2 treatment. Changes in immunologic markers on peripheral blood mononuclear cells determined by flow cytometry after anti-HER2 treatment Changes in tumor-derived gene mutations (e.g. PIK3CA, APOBEC3, CDH1…etc.) in ctDNA after anti-HER2 therapy Changes in proteins (e.g. HER2, HER3…etc.) and micro RNAs expression in extracellular vesicle after anti-HER2 therapy Changes in glycans and proteins expression in the plasma after anti-HER2 therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>HER2-positive Locally Advanced or Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Trastuzumab + chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trastuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel,Paclitaxel, nab-paclitaxel vinorelbine or eribulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab+ pertuzumab + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab+ pertuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel vinorelbine or eribulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <arm_group_label>Trastuzumab + chemotherapy</arm_group_label>
    <arm_group_label>Trastuzumab+ pertuzumab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <arm_group_label>Trastuzumab+ pertuzumab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Trastuzumab + chemotherapy</arm_group_label>
    <arm_group_label>Trastuzumab+ pertuzumab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Trastuzumab + chemotherapy</arm_group_label>
    <arm_group_label>Trastuzumab+ pertuzumab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <arm_group_label>Trastuzumab + chemotherapy</arm_group_label>
    <arm_group_label>Trastuzumab+ pertuzumab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <arm_group_label>Trastuzumab + chemotherapy</arm_group_label>
    <arm_group_label>Trastuzumab+ pertuzumab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin</intervention_name>
    <arm_group_label>Trastuzumab + chemotherapy</arm_group_label>
    <arm_group_label>Trastuzumab+ pertuzumab + chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed invasive breast cancer

          2. A confirmed HER2-positive status assessed by means of immunohistochemical analysis
             (with 3+ indicating positive status) and/or in situ hybridization (with an
             amplification ratio &gt; 2.0 indicating positive) by each institute

          3. History of pertuzumab and trastuzumab-containing chemotherapy for locally advanced
             and metastatic breast cancer(2 or 3 regimen as previous chemotherapy regimen for
             locally advanced or metastatic breast cancer). The latest regimen before enrollment
             dose not include pertuzumab.

          4. Patients have measurable and/or non-measurable disease according to RECIST ver1.1.

          5. Female patients and aged ≥ 20 years.

          6. Left Ventricular Ejection Fraction (LVEF) &gt; 50% at baseline (within 28 days before
             enrollment) as determined by either ECHO or MUGA

          7. Eastern Cooperative Oncology Group performance status of 0,1 or 2.

          8. Life expectancy of patients is expected at least 3 months.

          9. Signed and written informed consent (approved by the Institutional Review Board or
             Independent Ethics Committee) is obtained before any study procedure.

        Exclusion Criteria:

          1. History of chemotherapy &gt; 4 regimen for locally advance or metastatic disease except
             for cancer chemotherapeutic agent-free treatment regimen (eg, hormonal therapy alone,
             combination with hormonal therapy and trastuzumab and anti-HER2 therapy alone).

          2. Persistent Grade &gt;3 non-hematologic toxicity according to NCI-CTCAE v4.0-JCOG
             resulting from previous therapy at the time of enrollment.

          3. Symptomatic or uncontrolled central nervous system metastases.

          4. Multiple malignancies without history of breast cancer(within 10 years if invasive
             breast cancer and within 5 years if malignancies except invasive breast cancer)

          5. History of exposure to the following cumulative doses of anthracyclines:

               -  doxorubicin or liposomal doxorubicin &gt; 360 mg/m2

               -  epirubicin &gt; 720 mg/m2

               -  mitoxantrone &gt; 100 mg/m2

               -  If more than 1 anthracycline has been used, then the cumulative dose must not
                  exceed the equivalent of 360 mg/m2 of doxorubicin.

          6. Current uncontrolled hypertension (systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg)
             or unstable angina.

          7. History of CHF of any New York Heart Association criteria, or serious cardiac
             arrhythmia requiring treatment (exception, atrial fibrillation, paroxysmal
             supraventricular tachycardia).

          8. History of myocardial infarction within 6 months of enrollment.

          9. Dyspnea at rest due to complications of advanced malignancy.

         10. Inadequate organ function, as determined by the following laboratory results, within
             28 days before enrollment:

               -  Absolute neutrophil count &lt; 1,500/mm3

               -  Platelet count &lt; 100,000/mm3

               -  Hemoglobin &lt; 8.0 g/dL

               -  Total bilirubin &gt; 2.0 mg/dL, unless the patient has documented Gilbert's
                  syndrome

               -  Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT])
                  &gt; 100IU /L with the following exception (If considered that the liver
                  dysfunction due to liver metastases &gt; 200 IU/L, or 100 &lt; , ≤200 IU/L with serum
                  albumin &lt; 2.5 g/dL)

               -  Serum creatinine value &gt; 2.0 mg/dL or 177 μmol/L

         11. Current severe uncontrolled systemic disease(eg. Clinically significant
             cardiovascular, pulmonary and metabolic disease, disorder of wound healing, ulcer and
             fracture)

         12. Uncontrolled malignancy-associated hypercalcemia syndrome under bisphosphonates or
             denosumab treatment.

         13. Radiation related grade &gt;2 adverse event within 14 days before enrollment.

         14. Major surgical procedure or significant traumatic injury within 28 days before
             enrollment or anticipation of need for major surgery during the course of study
             treatment.

         15. Pregnant woman or positive pregnancy test.

         16. Nursing woman

         17. History of receiving any investigational treatment within 28 days before enrollment.

         18. Current known and active infection with human immunodeficiency virus, hepatitis B
             virus or hepatitis C virus.

         19. Receipt of intravenous antibiotics for infection within 14 days before enrollment.

         20. Current chronic daily treatment (continuous for &gt; 3 months) with corticosteroids
             (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled
             steroids.

         21. Known hypersensitivity to pertuzumab or trastuzumab without infusion reaction related
             to these drugs

         22. Assessed by the investigator to be unable or unwilling to comply with the
             requirements of the protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yutaka Yamamoto, MD, PhD</last_name>
    <phone>+81-96-373-5521</phone>
    <email>ys-yama@triton.ocn.ne.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Chikusa-ku</city>
        <state>Aichi</state>
        <zip>4648681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroji Iwata, MD, PhD</last_name>
      <phone>+81-52-762-6111</phone>
    </contact>
    <investigator>
      <last_name>Hiroji Iwata, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto City</city>
        <state>Kumamoto</state>
        <zip>8608556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yutaka Yamamoto, MD, PhD</last_name>
      <phone>+81-96-373-5521</phone>
    </contact>
    <investigator>
      <last_name>Yutaka Yamamoto, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Japan Breast Cancer Research Group</name>
      <address>
        <city>Chuo-ku, Nihonbashi, Koami-cho</city>
        <state>Tokyo</state>
        <zip>1030016</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+81-3-6264-8873</phone>
      <email>office@jbcrg.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>July 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
